Literature DB >> 8833762

Dopamine D3 receptors in the basal ganglia of the common marmoset and following MPTP and L-DOPA treatment.

M J Hurley1, J Jolkkonen, C M Stubbs, P Jenner, C D Marsden.   

Abstract

The distribution of the dopamine D3 receptor was studied by receptor autoradiography using [3H]7-OH-DPAT in striatal and extrastriatal brain regions of the common marmoset (Callithrix jacchus). Saturation studies demonstrated that [3H]7-OH-DPAT bound with similar affinity to different regions of marmoset brain. In normal marmosets, specific [3H]7-OH-DPAT binding was found in both striatal and extrastriatal regions. Very high levels of specific [3H]7-OH-DPAT binding were detected in the islands of Calleja and nucleus accumbens but in addition high levels of binding were detected in rostral caudate nucleus and putamen. In common marmosets treated with the selective nigral neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), the levels of specific [3H]7-OH-DPAT binding in striatal and extrastriatal regions were not different to those in normal animals. Chronic treatment of MPTP-treated marmosets with L-DOPA/ carbidopa did not alter the levels of specific [3H]7-OH-DPAT binding in any brain region. These results demonstrate that in common marmosets D3 receptors are located in both striatal and limbic regions. The receptor density is not altered by dopaminergic denervation or by chronic L-DOPA administration. The D3 receptor may, therefore, be important in both the therapeutic and adverse effects of drugs used to treat Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8833762     DOI: 10.1016/0006-8993(95)01309-1

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  9 in total

1.  Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells.

Authors:  M C Coldwell; I Boyfield; T Brown; J J Hagan; D N Middlemiss
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

2.  Extrastriatal D2-like receptors modulate basal ganglia pathways in normal and Parkinsonian monkeys.

Authors:  Arash Hadipour-Niktarash; Karen S Rommelfanger; Gunasingh J Masilamoni; Yoland Smith; Thomas Wichmann
Journal:  J Neurophysiol       Date:  2011-11-30       Impact factor: 2.714

3.  Maladaptive striatal plasticity in L-DOPA-induced dyskinesia.

Authors:  M Angela Cenci; Christine Konradi
Journal:  Prog Brain Res       Date:  2010       Impact factor: 2.453

4.  Regulation of dopamine D₃ receptor in the striatal regions and substantia nigra in diffuse Lewy body disease.

Authors:  J Sun; N J Cairns; J S Perlmutter; R H Mach; J Xu
Journal:  Neuroscience       Date:  2013-06-01       Impact factor: 3.590

Review 5.  Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.

Authors:  Susan Duty; Peter Jenner
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

6.  Striatal Signaling in L-DOPA-Induced Dyskinesia: Common Mechanisms with Drug Abuse and Long Term Memory Involving D1 Dopamine Receptor Stimulation.

Authors:  Mario Gustavo Murer; Rosario Moratalla
Journal:  Front Neuroanat       Date:  2011-08-11       Impact factor: 3.856

Review 7.  Neurobiological and Pharmacological Perspectives of D3 Receptors in Parkinson's Disease.

Authors:  Abdeslam Chagraoui; Giuseppe Di Giovanni; Philippe De Deurwaerdère
Journal:  Biomolecules       Date:  2022-02-01

8.  Dopamine D1, D2, D3 receptors, vesicular monoamine transporter type-2 (VMAT2) and dopamine transporter (DAT) densities in aged human brain.

Authors:  Jianjun Sun; Jinbin Xu; Nigel J Cairns; Joel S Perlmutter; Robert H Mach
Journal:  PLoS One       Date:  2012-11-21       Impact factor: 3.240

9.  D2 receptors and cognitive flexibility in marmosets: tri-phasic dose-response effects of intra-striatal quinpirole on serial reversal performance.

Authors:  Nicole K Horst; Bianca Jupp; Angela C Roberts; Trevor W Robbins
Journal:  Neuropsychopharmacology       Date:  2018-11-15       Impact factor: 7.853

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.